首页> 外文期刊>ESC Heart Failure >Pulmonary function assessment post‐left ventricular assist device implantation
【24h】

Pulmonary function assessment post‐left ventricular assist device implantation

机译:左心室辅助装置植入后的肺功能评估

获取原文
           

摘要

Aim The lungs—and particularly the alveolar‐capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long‐term effects of CF pumps on respiratory function. Methods and results We conducted a retrospective study of patients with end‐stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1?s (FEV 1 )] and diffusing capacity of the lung for carbon monoxide ( D LCO ) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end‐stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9)?years; male sex, n ?=?33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237?days post‐LVAD implantation, we observed significant D LCO decrease (?23%) since pre‐implantation ( P ??0.001). Δ D LCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre‐LVAD to post‐LVAD implantation: Δ D LCO to ΔPCWP ( r ?=?0.50, P ??0.01) and Δ D LCO to ΔRAP ( r ?=?0.39, P ??0.05). We observed other reductions in FEV 1 , FVC, and FEV 1 /FVC between pre‐LVAD and post‐LVAD implantation. In mean (SD) values, FEV 1 changed from 2.3 (0.7) to 2.1 (0.7) ( P ?=?0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) ( P ?=?0.01); and FEV 1 /FVC went from 0.72 (0.1) to 0.72 (0.1) ( P ?=?0.50). Landmark survival analysis revealed that Δ D LCO from 6?months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P ?=?0.03]. Conclusions Pulmonary function did not improve after LVAD implantation. The degree of D LCO deterioration is related to haemodynamic status post‐LVAD implantation. The Δ D LCO within 6?months post‐operative was associated with survival.
机译:目的肺(尤其是肺泡-毛细血管膜)可能对持续性血流(CF)和心力衰竭(HF)中的肺动脉压力改变敏感。我们旨在研究CF泵对呼吸功能的长期影响。方法和结果我们对本机构的晚期HF患者进行了回顾性研究。我们分析了肺功能测试[例如左心室辅助装置(LVAD)植入前后前后的肺活量(FVC)和强制呼气量(FEV 1)]和肺对一氧化碳(DLCO)的扩散能力,并将其与有创血流动力学进行比较学习。在筛查的274例患者中,最终研究分析涉及2007年2月1日至2015年12月31日期间在我们机构接受CF LVAD植入的44例末期HF患者。这些患者[平均(标准差,SD)年龄为50(9)?岁;男性,n = 33,75%]接受了HeartMate II(Thoratec Corp.)泵(77%)或HeartWare(HeartWare International Inc.)泵。左室射血分数的平均值(SD)为21%(13%)。 LVAD植入后中位数为237天,我们观察到自植入前以来D LCO显着降低(?23%)(P 0.001)。 ΔD LCO与LVAD植入前至LVAD植入后肺毛细血管楔压(PCWP)和右心房压力(RAP)的变化呈负相关:ΔD LCO到ΔPCWP(r =?0.50,P?<? 0.01)和ΔD LCO到ΔRAP(r = 0.39,P <0.05)。我们观察到LVAD植入前和LVAD植入后FEV 1,FVC和FEV 1 / FVC的其他降低。在平均值(SD)值中,FEV 1从2.3(0.7)变为2.1(0.7)(P = 0.005); FVC从3.2(0.8)降至2.9(0.9)(P = 0.01); FEV 1 / FVC从0.72(0.1)变为0.72(0.1)(P≤0.50)。具有里程碑意义的生存分析表明,LVAD植入后6个月的ΔD LCO可以预测HF患者的死亡[危险比(95%置信区间)为0.60(0.28-0.98); P≥0.03]。结论LVAD植入后肺功能并未改善。 D LCO恶化的程度与LVAD植入后的血流动力学状态有关。术后6个月内的ΔD LCO与生存率有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号